164 related articles for article (PubMed ID: 34333790)
1. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Bosch J; Chung C; Carrasco-Zevallos OM; Harrison SA; Abdelmalek MF; Shiffman ML; Rockey DC; Shanis Z; Juyal D; Pokkalla H; Le QH; Resnick M; Montalto M; Beck AH; Wapinski I; Han L; Jia C; Goodman Z; Afdhal N; Myers RP; Sanyal AJ
Hepatology; 2021 Dec; 74(6):3146-3160. PubMed ID: 34333790
[TBL] [Abstract][Full Text] [Related]
2. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.
Noureddin M; Goodman Z; Tai D; Chng ELK; Ren Y; Boudes P; Shlevin H; Garcia-Tsao G; Harrison SA; Chalasani NP
Aliment Pharmacol Ther; 2023 Feb; 57(4):409-417. PubMed ID: 36647687
[TBL] [Abstract][Full Text] [Related]
3. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
[TBL] [Abstract][Full Text] [Related]
4. The impact of hepatic steatosis on portal hypertension.
Semmler G; Scheiner B; Schwabl P; Bucsics T; Paternostro R; Chromy D; Stättermayer AF; Trauner M; Mandorfer M; Ferlitsch A; Reiberger T
PLoS One; 2019; 14(11):e0224506. PubMed ID: 31693695
[TBL] [Abstract][Full Text] [Related]
5. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
Chalasani N; Abdelmalek MF; Garcia-Tsao G; Vuppalanchi R; Alkhouri N; Rinella M; Noureddin M; Pyko M; Shiffman M; Sanyal A; Allgood A; Shlevin H; Horton R; Zomer E; Irish W; Goodman Z; Harrison SA; Traber PG;
Gastroenterology; 2020 Apr; 158(5):1334-1345.e5. PubMed ID: 31812510
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.
Simbrunner B; Marculescu R; Scheiner B; Schwabl P; Bucsics T; Stadlmann A; Bauer DJM; Paternostro R; Eigenbauer E; Pinter M; Stättermayer AF; Trauner M; Mandorfer M; Reiberger T
Liver Int; 2020 Jul; 40(7):1713-1724. PubMed ID: 32358998
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
[TBL] [Abstract][Full Text] [Related]
11. Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension.
Sartoris R; Rautou PE; Elkrief L; Pollorsi G; Durand F; Valla D; Spahr L; Terraz S; Soubrane O; Cauchy F; Vilgrain V; Ronot M
Radiology; 2018 Dec; 289(3):698-707. PubMed ID: 30179109
[TBL] [Abstract][Full Text] [Related]
12. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.
Semmler G; Stift J; Scheiner B; Wöran K; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Pinter M; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
Dig Dis Sci; 2019 Dec; 64(12):3642-3651. PubMed ID: 31209721
[TBL] [Abstract][Full Text] [Related]
13. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab-based model.
Rabiee A; Deng Y; Ciarleglio M; Chan JL; Pons M; Genesca J; Garcia-Tsao G
Hepatol Commun; 2022 Dec; 6(12):3324-3334. PubMed ID: 36214066
[TBL] [Abstract][Full Text] [Related]
15. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension.
Berzigotti A; Rossi V; Tiani C; Pierpaoli L; Zappoli P; Riili A; Serra C; Andreone P; Morelli MC; Golfieri R; Rossi C; Magalotti D; Zoli M
J Gastroenterol; 2011 May; 46(5):687-95. PubMed ID: 21213113
[TBL] [Abstract][Full Text] [Related]
17. Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma.
Souhami A; Sartoris R; Rautou PE; Cauchy F; Bouattour M; Durand F; Giannelli V; Gigante E; Castera L; Valla D; Soubrane O; Vilgrain V; Ronot M
JHEP Rep; 2020 Oct; 2(5):100147. PubMed ID: 32885156
[TBL] [Abstract][Full Text] [Related]
18. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
Jindal A; Agarwal S; Sharma S; Kumar M; Saraya A; Sarin SK
Dig Dis Sci; 2023 May; 68(5):2149-2157. PubMed ID: 36562888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
